Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck’s Keytruda: The ‘Wall Of Data’ Still Holds After ODAC Look Back

May 06 2021

• By Michael McCaughan

Related Content

FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo

Apr 30 2021

Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says

Apr 30 2021

Keytruda And FDA’s Oncology Center of Excellence: The Regulatory Milestones Keep Coming

Jul 02 2020

After ODAC: The State Of Accelerated Approval At The US FDA

May 06 2021

Merck Drives Into Immunotherapy “Wild West” With New Trials

Jun 23 2014

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Genentech, Inc.

Additional Topics

United States Advisory Committees Review Pathway ImmunoOncology Regulation Clinical Trials Drug Approval Standards Drug Review Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window